Department of Obstetrics and Gynecology, The Second Xiangya Hospital, Central South University, Changsha Hunan 410000, PR China.
Department of Obstetrics and Gynecology, The Second Xiangya Hospital, Central South University, Changsha Hunan 410000, PR China.
Reprod Biomed Online. 2021 Jun;42(6):1057-1066. doi: 10.1016/j.rbmo.2021.02.004. Epub 2021 Feb 12.
Endometriosis is a common and complicated gynaecologic disease. Long non-coding RNA CDKN2B-AS1 plays a crucial role in the development and progression of several cancers. Whether CDKN2B-AS1 contributes to endometriosis, however, remains unknown.
Cellular proliferation, invasion and DNA synthesis abilities were assessed by CCK8, transwell and 5-ethynyle-2'-deoxyuridine assays. The expression of epithelial-mesenchymal transition markers and three isoforms of AKT was detected using Western blot. Real-time polymerase chain reaction was used to determine the relative expression levels of CDKN2B-AS1 and candidate miRNAs in ectopic, eutopic endometria and normal endometrial tissues. The relationship between CDKN2B-AS1 and miRNA was determined by luciferase reporter assays.
The relative expression level of CDKN2B-AS1 was up-regulated in eutopic and ectopic endometria. In endometrial stromal cells and Ishikawa cells, CDKN2B-AS1 overexpression promoted cellular proliferation and invasion, and increased the protein expression of vimentin but decreased the expression of E-cadherin. miR-424-5p was confirmed the target of CDKN2B-AS1 through bioinformatics tools and luciferase reporter assays. In addition, the enhanced effect of cellular phenotype of CDKN2B-AS1 overexpression was significantly attenuated by miR-424-5p overexpression. Furthermore, miR-424-5p was able to directly target AKT3 through luciferase reporter assay. Mechanistically, CDKN2B-AS1 acts as a ceRNA by sponging miR-424-5p and targets AKT3.
The cellular mechanism of CDKN2B-AS1 in endometriosis was confirmed; CDKN2B-AS1 may be a potential target for ovarian endometriosis therapy.
子宫内膜异位症是一种常见且复杂的妇科疾病。长链非编码 RNA CDKN2B-AS1 在几种癌症的发生和发展中起着至关重要的作用。然而,CDKN2B-AS1 是否有助于子宫内膜异位症的发生尚不清楚。
通过 CCK8、Transwell 和 5-乙炔基-2'-脱氧尿苷测定评估细胞增殖、侵袭和 DNA 合成能力。使用 Western blot 检测上皮-间充质转化标志物和 AKT 的三种同工型的表达。实时聚合酶链反应用于确定异位、在位子宫内膜和正常子宫内膜组织中 CDKN2B-AS1 和候选 miRNA 的相对表达水平。通过荧光素酶报告基因测定确定 CDKN2B-AS1 与 miRNA 之间的关系。
CDKN2B-AS1 的相对表达水平在上皮和异位子宫内膜中上调。在子宫内膜基质细胞和 Ishikawa 细胞中,CDKN2B-AS1 的过表达促进了细胞增殖和侵袭,并增加了波形蛋白的蛋白表达,而降低了 E-钙粘蛋白的表达。通过生物信息学工具和荧光素酶报告基因测定证实 miR-424-5p 是 CDKN2B-AS1 的靶标。此外,miR-424-5p 过表达显著减弱了 CDKN2B-AS1 过表达对细胞表型的增强作用。此外,通过荧光素酶报告基因测定证实 miR-424-5p 能够直接靶向 AKT3。机制上,CDKN2B-AS1 通过海绵吸附 miR-424-5p 并靶向 AKT3 发挥 ceRNA 作用。
证实了 CDKN2B-AS1 在子宫内膜异位症中的细胞机制;CDKN2B-AS1 可能是卵巢子宫内膜异位症治疗的潜在靶点。